GNPX — Genprex, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1595248 ·
Last close
$3.29
Market Cap
$2.70M
52W High
$1210.00
52W Low
$3.26
ADV30
307,720
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,483,984 | -4,447,219 | 17,136,916 | 15,154,203 | 2,341,864 |
| Mar 2026 | 0 | — | -4,494,184 | -4,461,895 | 20,306,266 | 18,049,255 | 3,375,996 |
| Dec 2025 | 0 | — | -3,518,632 | -3,790,211 | 10,159,011 | 7,830,855 | 2,197,135 |
| Sep 2025 | 0 | — | -3,345,913 | -3,799,240 | 3,562,513 | 1,103,315 | 2,794,706 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,288,242
Investing CF
$0
Financing CF
$28,869,159
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-596.64
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-175,490,291
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-16,025,484
Pretax Income TTM
$-16,726,247
Interest Exp TTM
$739,935
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,515,619 | -16,228,953 | 10,159,011 | 2,197,135 | 7,961,876 | -15,311,209 |
| Dec 2024 | 0 | -21,174,167 | -21,111,163 | 4,124,325 | 2,504,170 | 1,620,155 | -17,922,566 |
| Dec 2023 | 0 | -31,056,894 | -30,860,461 | 10,670,592 | 3,254,208 | 7,416,384 | -24,738,603 |
| Dec 2022 | 0 | -23,830,719 | -23,740,621 | 25,085,027 | 2,810,287 | 22,274,740 | -17,621,498 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.18
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VBIO | Valion Bio, Inc. | $2.69M | $3.03 | — |
| CASIF | CASI Pharmaceuticals, Inc. | $2.67M | $0.13 | — |
| TCRT | Alaunos Therapeutics, Inc. | $2.77M | $1.09 | — |
| VCNX | VACCINEX, INC. | $2.60M | $0.97 | — |
| ISCO | International Stem Cell CORP | $2.80M | $0.35 | — |
News headlines (Yahoo Finance, 1h cache)
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
2026-09-01 12:00 · Yahoo
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
2026-08-18 11:00 · Yahoo
Genprex Shares Rise After Collaboration With Roche Diagnostics
2026-08-03 12:46 · Yahoo
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
2026-08-03 11:00 · Yahoo
Genprex’s Reqorsa combo secures Canadian patent for lung cancer
2026-06-23 10:51 · Yahoo
Genprex to Participate at BIO International Convention 2026
2026-06-17 13:00 · Yahoo
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
2026-05-26 12:00 · Yahoo
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
2026-04-30 12:00 · Yahoo
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
2026-04-21 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.